Doxorubicin (DOX) is one of the most effective antineoplastic drugs. However, its clinical use is largely limited by potential dose-dependent cardiotoxicity. To date, the mechanisms of DOX-induced cardiotoxicity remains incompletely understood. More importantly, no efficient therapeutic strategy is available to counteract DOX-induced cardiomyopathy, underscoring the importance of the prevention of this disease. In this chapter, we first describe the pathophysiology of DOX-induced cardiotoxicity. We then update the findings of molecular biology of DOX-induced cardiomyopathy including molecular mechanisms, established and putative biomarkers for early diagnosis, and potential genetic factors for prediction of susceptibility. Finally, we introduce a number of pharmaceutical measures and practical lifestyle modifications for the prevention of this disease.
Part of the book: Cardiotoxicity